Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes

Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular... Introduction: The purpose of this study was to evaluate the outcomes of loading-phase treatment with intravitreal aflibercept (IVA) or brolucizumab (IVBr) for treatment-naïve neovascular age-related macular degeneration (nAMD) associated with type 1 macular neovascularization (MNV). Methods: We retrospectively studied 108 consecutive eyes undergoing IVA and 103 consecutive eyes administered IVBr. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), dry macula achievement, polypoidal lesion regression, and development of intraocular inflammation (IOI) were all assessed. Results: During the loading-phase treatment, IOI was detected in 18 eyes (17.5%) in the IVBr but none of those in the IVA group (p < 0.01). The loading-phase treatment was completed in 101 eyes in the IVA and 85 eyes in the IVBr group. In those cases, BCVA improved significantly, and CMT and CCT showed significant reductions after the loading-phase treatment in both groups (all p < 0.01). The CCT reduction was significantly greater with IVBr than with IVA (32 ± 28 μm vs. 40 ± 25 μm, p < 0.01). The dry macula achievement rate was significantly higher in the IVBr than in the IVA group (71.3 vs. 85.9%, p < 0.05). We observed complete regression of polypoidal lesions significantly more frequently with IVBr than with IVA (47.5 vs. 77.3%, p < 0.01). Discussion/Conclusion: Loading-phase treatment with IVA or IVBr for treatment-naïve nAMD with type 1 MNV effectively improved BCVA and diminished exudative changes. The CCT reduction, dry macula achievement, and polypoidal lesion regression rates were all significantly greater in the IVBr than in the IVA group. The incidence of IOI was significantly higher with IVBr than with IVA. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Ophthalmologica Karger

Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes

Download PDF
8 pages

Loading next page...
 
/lp/karger/intravitreal-aflibercept-versus-brolucizumab-for-treatment-naive-0m0rQR8deM

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 2022 S. Karger AG, Basel
ISSN
0030-3755
eISSN
1423-0267
DOI
10.1159/000526044
Publisher site
See Article on Publisher Site

Abstract

Introduction: The purpose of this study was to evaluate the outcomes of loading-phase treatment with intravitreal aflibercept (IVA) or brolucizumab (IVBr) for treatment-naïve neovascular age-related macular degeneration (nAMD) associated with type 1 macular neovascularization (MNV). Methods: We retrospectively studied 108 consecutive eyes undergoing IVA and 103 consecutive eyes administered IVBr. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), dry macula achievement, polypoidal lesion regression, and development of intraocular inflammation (IOI) were all assessed. Results: During the loading-phase treatment, IOI was detected in 18 eyes (17.5%) in the IVBr but none of those in the IVA group (p < 0.01). The loading-phase treatment was completed in 101 eyes in the IVA and 85 eyes in the IVBr group. In those cases, BCVA improved significantly, and CMT and CCT showed significant reductions after the loading-phase treatment in both groups (all p < 0.01). The CCT reduction was significantly greater with IVBr than with IVA (32 ± 28 μm vs. 40 ± 25 μm, p < 0.01). The dry macula achievement rate was significantly higher in the IVBr than in the IVA group (71.3 vs. 85.9%, p < 0.05). We observed complete regression of polypoidal lesions significantly more frequently with IVBr than with IVA (47.5 vs. 77.3%, p < 0.01). Discussion/Conclusion: Loading-phase treatment with IVA or IVBr for treatment-naïve nAMD with type 1 MNV effectively improved BCVA and diminished exudative changes. The CCT reduction, dry macula achievement, and polypoidal lesion regression rates were all significantly greater in the IVBr than in the IVA group. The incidence of IOI was significantly higher with IVBr than with IVA.

Journal

Ophthalmologica – Karger

Published: Nov 1, 2022

Keywords: Aflibercept; Brolucizumab; Loading-phase treatment; Neovascular age-related macular degeneration; Type 1 macular neovascularization

References

  • The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis
    Wong, TY; Wong, T; Chakravarthy, U; Klein, R; Mitchell, P; Zlateva, G
  • An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group
    Bird, AC; Bressler, NM; Bressler, SB; Chisholm, IH; Coscas, G; Davis, MD
  • Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group
    Spaide, RF; Jaffe, GJ; Sarraf, D; Freund, KB; Sadda, SR; Staurenghi, G
  • Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration
    Nguyen, QD; Das, A; Do, DV; Dugel, PU; Gomes, A; Holz, FG
  • HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration
    Dugel, PU; Koh, A; Ogura, Y; Jaffe, GJ; Schmidt-Erfurth, U; Brown, DM
  • HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration
    Dugel, PU; Singh, RP; Koh, A; Ogura, Y; Weissgerber, G; Gedif, K
  • Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
    Matsumoto, H; Hoshino, J; Mukai, R; Nakamura, K; Akiyama, H
  • Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy
    Fukuda, Y; Sakurada, Y; Matsubara, M; Hasebe, Y; Sugiyama, A; Kikushima, W
  • Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study
    Maruko, I; Okada, AA; Iida, T; Hasegawa, T; Izumi, T; Kawai, M
  • Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER
    Mones, J; Srivastava, SK; Jaffe, GJ; Tadayoni, R; Albini, TA; Kaiser, PK
  • Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration
    Mukai, R; Matsumoto, H; Akiyama, H
  • Assessing characteristics of patients with or without intraocular inflammation (IOI) in the brolucizumab treatment arms from the HAWK and HARRIER, phase 3 studies
    Heier, JS; Rosenbaum, JT; Barakat, MR; Khanani, AM; Singer, M; Dick, AD
  • Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results
    Koizumi, H; Kano, M; Yamamoto, A; Saito, M; Maruko, I; Sekiryu, T
  • Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials
    Yamashiro, K; Oishi, A; Hata, M; Takahashi, A; Tsujikawa, A
  • EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy
    Koh, A; Lee, WK; Chen, LJ; Chen, SJ; Hashad, Y; Kim, H
  • Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial
    Koh, A; Lai, TYY; Takahashi, K; Wong, TY; Chen, LJ; Ruamviboonsuk, P
  • Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study
    Koizumi, H; Kano, M; Yamamoto, A; Saito, M; Maruko, I; Sekiryu, T
  • Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy
    Morimoto, M; Matsumoto, H; Mimura, K; Akiyama, H
  • Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy
    Kikushima, W; Sakurada, Y; Sugiyama, A; Tanabe, N; Kume, A; Iijima, H
  • Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy
    Cho, JH; Ryoo, NK; Cho, KH; Park, SJ; Park, KH; Woo, SJ
  • Pachychoroid neovasculopathy
    Pang, CE; Freund, KB
  • Pachychoroid disease: a new perspective on exudative maculopathy
    Yanagi, Y
  • Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab
    Baumal, CR; Spaide, RF; Vajzovic, L; Freund, KB; Walter, SD; John, V
  • Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
    Haug, SJ; Hien, DL; Uludag, G; Ngoc, TTT; Lajevardi, S; Halim, MS
  • Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations
    Jain, A; Chea, S; Matsumiya, W; Halim, MS; Yasar, C; Kuang, G
  • Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment
    Baumal, CR; Bodaghi, B; Singer, M; Tanzer, DJ; Seres, A; Joshi, MR